Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8

Clinical and Vaccine Immunology

Volumn 18, Issue 1, 2011, Pages 59-66

  Yano, Masahide ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; PHOSPHORYLCHOLINE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; IMMUNOGLOBULIN VARIABLE REGION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; GENES, IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; STRUCTURE-ACTIVITY RELATIONSHIP; TETANUS TOXOID; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 78650905191     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00368-10     Document Type: Article

References (55)

1. Anonymous. 2008. Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2008. MMWR Morb. Mortal. Wkly. Rep. 57:1148-1151.
2. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188:2381-2386.
3. Briles, D. E., J. L. Claflin, K. Schroer, and C. Forman. 1981. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294:88-90.
4. Briles, D. E., C. Forman, and M. Crain. 1992. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect. Immun. 60:1957-1962.
5. Briles, D. E., C. Forman, S. Hudak, and J. L. Claflin. 1982. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J. Exp. Med. 156:1177-1185.
6. Briles, D. E., et al. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J. Exp. Med. 153:694-705.
7. Buchwald, U. K., A. Lees, M. Steinitz, and L. A. Pirofski. 2005. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect. Immun. 73:325-333.
8. Buchwald, U. K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968.
9. Burns, T., M. Abadi, and L. A. Pirofski. 2005. Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide. Infect. Immun. 73:4530-4538.
10. Burns, T., Z. Zhong, M. Steinitz, and L. A. Pirofski. 2003. Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect. Immun. 71:6775-6783.
11. Carrero, J. J., et al. 2009. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol. Dial. Transplant. 24:3454-3460.
12. Casadevall, A., et al. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864-3872.
13. Cerny, J., J. S. Smith, C. Webb, and P. W. Tucker. 1988. Properties of anti-idiotypic T cell lines propagated with syngeneic B lymphocytes. I. T cells bind intact idiotypes and discriminate between the somatic idiotypic variants in a manner similar to the anti-idiotopic antibodies. J. Immunol. 141:3718-3725.
14. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect. Immun. 70:4977-4986.
15. Clarke, S. H., J. J. Kenny, D. G. Sieckmann, and S. Rudikoff. 1984. Amino acid sequence of a phosphocholine-binding antibody from an immune defective CBA/N mouse employing the T15 VH region associated with unusual DH, JH, and V kappa segments. J. Immunol. 132:1544-1549.
16. Cripps, A. W., D. C. Otczyk, and J. M. Kyd. 2005. Bacterial otitis media: a vaccine preventable disease? Vaccine 23:2304-2310.
17. Dagan, R. 2009. Serotype replacement in perspective. Vaccine 27(Suppl. 3):C22-C24.
18. Desaymard, C., A. M. Giusti, and M. D. Scharff. 1984. Rat anti-T15 monoclonal antibodies with specificity for VH- and VH-VL epitopes. Mol. Immunol. 21:961-967.
19. Diamond, B., and M. D. Scharff. 1984. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc. Natl. Acad. Sci. U. S. A. 81:5841-5844.
20. Ekdahl, K., J. H. Braconier, and C. Svanborg. 1997. Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection. Clin. Infect. Dis. 25:654-660.
21. Fabrizio, K., C. Manix, H. Tian, N. van Rooijen, and L. A. Pirofski. 2010. The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. Vaccine 28:7542-7550.
22. Foster, D., et al. 2008. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J. Med. Microbiol. 57:480-487.
23. Gillespie, S. H., et al. 1993. Species of alpha-hemolytic streptococci possessing a C-polysaccharide phosphorylcholine-containing antigen. Infect. Immun. 61:3076-3077.
24. Giusti, A. M., N. C. Chien, D. J. Zack, S. U. Shin, and M. D. Scharff. 1987. Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region. Proc. Natl. Acad. Sci. U. S. A. 84:2926-2930.
25. Gronlund, H., et al. 2009. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a populationbased cohort from northern Sweden. Eur. J. Cardiovasc. Prev. Rehabil. 16:382-386.
26. Guo, W. X., et al. 1997. Sequence changes at the V-D junction of the VH1 heavy chain of anti-phosphocholine antibodies alter binding to and protection against Streptococcus pneumoniae. Int. Immunol. 9:665-677.
27. Haas, K. M., J. C. Poe, D. A. Steeber, and T. F. Tedder. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23:7-18.
28. Hicks, L. A., et al. 2007. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
29. Jackson, L. A., et al. 2003. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348:1747-1755.
30. Jefferies, J. M., et al. 2007. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J. Infect. Dis. 196:936-944.
31. Jones, H. E., P. R. Taylor, E. McGreal, S. Zamze, and S. Y. Wong. 2009. The contribution of naturally occurring IgM antibodies, IgM cross-reactivity and complement dependency in murine humoral responses to pneumococcal capsular polysaccharides. Vaccine 27:5806-5815.
32. Kirkham, P. M., F. Mortari, J. A. Newton, and H. W. Schroeder, Jr. 1992. Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J. 11:603-609.
33. Maitta, R. W., et al. 2004. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect. Immun. 72:4810-4818.
34. Maitta, R. W., K. Datta, A. Lees, S. S. Belouski, and L. A. Pirofski. 2004. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect. Immun. 72:196-208.
35. Marks, M., et al. 2007. Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect. Immun. 75:1586-1597.
36. Mykietiuk, A., et al. 2006. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 25:457-462.
37. Nakouzi, A., and A. Casadevall. 2003. The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan. Mol. Immunol. 40:351-361.
38. O'Brien, K. L., et al. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
39. Rajam, G., et al. 2008. A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization. Microb. Pathog. 44:186-196.
40. Retter, I., H. H. Althaus, R. Munch, and W. Muller. 2005. VBASE2, an integrative V gene database. Nucleic Acids Res. 33:D671-D674.
41. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
42. Roush, S. W., and T. V. Murphy. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155-2163.
43. Russell, N. D., J. R. Corvalan, M. L. Gallo, C. G. Davis, and L. Pirofski. 2000. Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect. Immun. 68:1820-1826.
44. Skovsted, I. C., et al. 2007. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine 25:6490-6500.
45. Sorensen, U. B., R. Agger, J. Bennedsen, and J. Henrichsen. 1984. Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody. Infect. Immun. 43:876-878.
46. Spira, G., H. L. Aguila, and M. D. Scharff. 1988. T15 PC-binding monoclonal antibodies retain specificity when they switch from IgM to IgG. J. Immunol. 140:2675-2680.
47. Su, J., et al. 2006. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188:160-166. (Pubitemid 44160704)
48. Suresh, M. V., S. K. Singh, D. A. Ferguson, Jr., and A. Agrawal. 2007. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J. Immunol. 178:1158-1163.
49. Szu, S. C., S. Clarke, and J. B. Robbins. 1983. Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect. Immun. 39:993-999.
50. Tanaka, N., et al. 2007. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine 25:2680-2687.
51. Tian, H., A. Groner, M. Boes, and L. A. Pirofski. 2007. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect. Immun. 75:1643-1650.
52. Tian, H., S. Weber, P. Thorkildson, T. R. Kozel, and L. A. Pirofski. 2009. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect. Immun. 77:1502-1513.
53. van Dam, J. E., A. Fleer, and H. Snippe. 1990. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek 58:1-47.
54. Vollmer, W., and A. Tomasz. 2001. Identification of the teichoic acid phosphorylcholine esterase in Streptococcus pneumoniae. Mol. Microbiol. 39:1610-1622.
55. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.